{"paper_id":"4de85af9-3069-4f54-b38b-b2885a688f3f","body_text":"Chronic abnormal uterine bleedings and quality of women’s life. How to significantly improve the result?\nDOI:\nhttps://doi.org/10.18370/2309-4117.2020.51.14-22Keywords:\nabnormal uterine bleedings, iron deficiency, vitamin D, anemia, quality of women’s lifeAbstract\nPurpose of the study: to determine the effect of iron and vitamin D subsidies on the quality of women’s life who receive pathogenetic therapy for abnormal uterine bleedings (AUB) caused by adenomyosis and/or endometrial polyps.\nMaterials and methods. 114 patients with chronic AUB were randomized into two groups. The main group consist of 58 women, including 46 women with chronic AUB and adenomyosis (AUB-A), 12 women with adenomyosis and endometrial polyps (AUB-A,P). Women with AUB-A were prescribed 2 mg dienogest daily for the treatment of adenomyosis, similarly to patients with AUB-A,P after hysteroresection. All women in the main group also took a vitamin complex (iron, folate, iodine, vitamin D3, docosahexaenoic acid). The control group included 56 patients (43 women with AUB-A, 13 women with AUB-A,P) who were prescribed etiopathogenetic treatment (dienogest 2 mg per day and/or hysteroresection for endometrial polyps) without a vitamin complex subsidy. Quality of life was assessed using the SF-36 questionnaire. All patients received serum concentrations of hemoglobin, ferritin and 25(OH)D before and 3 months after treatment.\nResults. Iron-free dienogest therapy led to an increase serum hemoglobin levels after 3 months (p = 0.001). After three months vitamin complex Pregna-5 added there were significantly increased of hemoglobin levels, ferritin and 25(OH)D. This is accompanied by an improvement in the overall indicator of physical (r = 0.421, p <0.05) and psychological health (r = 0.385, p <0.05) on the SF-36 scale. An increase in serum ferritin greatly improves the psychological (r = 0.660, p <0.05) and physical components of women’s health (r = 0.522, p <0.05). Optimization of serum vitamin D levels improves physical health (r = 0.494, p <0.05). Conclusions. It is necessary to combine etiopathogenetic therapy with additional sources of vitamin D and iron for successful therapy of AUB and restoration of deficient conditions. This is significantly improves the quality of life.References\n- Antypkin, Y.G., Kaminskyi, V.V., Tatarchuk, T.F. “Optimization of family planning service in ukraine in the realization of modern strategy of woman health maintenance.” Reproductive endocrinology 3.35 (2017): 7–10. DOI: 10.18370/2309-4117.2017.35.7-16\n- Bodnar, P.M., Mikhalchyshyn, G.P. “Iodine deficiency diseases and their prevention.” International Journal of Endocrinology 4.6 (2006).\n- Zaporozhan, V.M., Tatarchuk. T.F., Ber, A., et al. “National consensus of management patients with abnormal uterine bleeding by association of gynecologist and endocrinologist of Ukraine.” Reproductive endocrinology 1.21 (2015): 7–12. DOI: 10.18370/2309-4117.2015.21.7-14\n- Zaporozhan, V.M., Tatarchuk. T.F., Kaminskyi, V.V., et al. “National consensus on management patients with endometriosis.” Reproductive endocrinology 4.24 (2015): 7–12. DOI: 10.18370/2309-4117.2015.24.7-12\n- Ministry of Health of Ukraine. “Order No. 353 from April 13, 2016 «Unified clinical protocol of primary, secondary (specialized) and tertiary (highly specialized) medical care. Abnormal uterine bleeding.”\n- Povorozniuk, V.V., Balatska, N.I. “Deficiency of vitamin D among ukrainian population: risk-factors of development.” Reproductive endocrinology 5.13 (2013): 7–13. DOI: 10.18370/2309-4117.2013.13.7-13\n- Tatarchuk, T.F., Yefimenko, O.A., Shevchuk, T.V. “Current management of abnormal uterine bleeding.” Reproductive endocrinology 4.12 (2013): 18–27. DOI: 10.18370/2309-4117.2013.12.18-28\n- Antypkin, Y.G., Vdovychenko, Y.P., Graziottin, A., et al. “Uterine bleedings and quality of woman's life: Resolution of advisory board.” Reproductive Endocrinology 3.47 (2019): 13–18. DOI: 10.18370/2309-4117.2019.47.8-12\n- Rusińska, A., Płudowski, P., Zygmunt, A. “Vitamin D Supplementation Guidelines for General Population and Groups at Risk of Vitamin D Deficiency in Poland – Recommendations of the Polish Society of Pediatric Endocrinology and Diabetes and the Expert Panel With Participation of National Specialist Consultants and Representatives of Scientific Societies – 2018 Update.” Front Endocrinol (Lausanne) 9 (2018): 246.\n- Bener, A., Kamal, M. “Higher Prevalence of Iron Deficiency as Strong Predictor of Attention Deficit Hyperactivity Disorder in Children.” Ann Med Health Sci Res 4.3 (2014): S291–S297.\n- Cooke, A.G., McCavit, T.L., Buchanan, G.R., Powers, J.M. “Iron Deficiency Anemia in Adolescents Who Present with Heavy Menstrual Bleeding.” J Pediatr Adolesc Gynecol 30.2 (2017): 247–50.\n- Wallace, D.F. “The Regulation of Iron Absorption and Homeostasis.” Biochem Rev 37.2 (2016): 51–62.\n- Edwards, M.H., Cole, Z.A., Harvey, N.C., Cooper, C. “The global epidemiology of vitamin D status.” The Journal of Aging Research & Lifestyle (2017)/ Available from: [ www.jarlife.net/703-the-global-epidemiology-of-vitamin-d-status.html].\n- Davis, E., Sparzak, P.B. “Abnormal Uterine Bleeding (Dysfunctional Uterine Bleeding).” StatPearls (2019). Available from: [http://www.ncbi.nlm.nih.gov/books/NBK532913/].\n- Graziottin, A. “The shorter, the better: A review of the evidence for a shorter contraceptive hormone-free interval.” Eur J Contracept Reprod Health Care 21.2 (2016): 93–105.\n- World Health Organization. Guideline: Daily iron and folic acid supplementation in pregnant women. Geneva. WHO (2012).\n- Intira Sriprasert, Tarita Pakrashi, David F. Archer. “Heavy menstrual bleeding diagnosis and medical management.” Contracept Reprod Med 2 (2017): 20.\n- The United Nations University. “Iodine deficiency in 2007: Global progress since 2003.” Food and Nutrition Bulletin 29.3 (2008).\n- World Health Organization. Iron deficiency anemia assessment, prevention and control. A guid for programme managers. Geneva. WHO (2001).\n- Lins, L., Carvalho, F.M. “SF-36 total score as a single measure of health-related quality of life: Scoping review.” SAGE Open Med 4 (2016): 2050312116671725\n- Whitaker, L., Critchley, H.O.D. “Abnormal uterine bleeding.” Best Practice & Research Clinical Obstetrics & Gynaecology 34 (2016): 54–65.\n- Holick, M.F., Binkley, N.C., Bischoff-Ferrari,H.A., et al. “Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline.” The Journal of Clinical Endocrinology & Metabolism 96.7 (2011): 1911–30.\n- Munro, M.G., Critchley, H.O.D., Broder, M.S., Fraser, I.S. “FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age.” Intern J Gynecol Obstet 1.13 (2011): 3–13.\n- Munro, M.G., Critchley, H.O.D., Fraser, I.S., FIGO Menstrual Disorders Committee. “The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions.” International Journal of Gynecology & Obstetrics 143.3 (2018): 393–408.\n- National Collaborating Centre for Women’s and Children’s Health. Heavy menstrual bleeding clinical guideline (2007).\n- National Institute for Clinical Excellence. Guideline Development Methods: Information for National Collaborating Centres and Guideline Developers. London. NICE (2005).\n- Nishimura, M., Yaguti, H., Yoshitsugu, H. “Tissue distribution of mRNA expression of human cytochrome P–450 isoforms assessed by high-sensivity real-time reverse transcription PCR.” Yakugaku Zasshi 123.5 (2003): 369–75.\n- American College of Obstetricians and Gynecologists. “Practice Bulletin No. 128. Diagnosis of abnormal uterine bleeding in reproductiveaged women.” Obstet Gynecol 120 (2012): 197–206.\n- Scaglione, F., Panzavolta, G. “Folate, folic acid and 5-methyltetrahydrofolate are not the same thing.” Xenobiotica 44.5 (2014): 480–8.\n- Shelnutt, K.P., et al. “Methylenetetrahydrofolate reductase 677C–>T polymorphism affects DNA methylation in response to controlled folate intake in young women.” J Nutr Biochem 15.9 (2004): 554–60.\n- Tatarchuk, T.F., Kosei, N.V., Tutchenko, T.M. “Current diagnosis and treatment of abnormal uterine bleeding.” Reproductive Endocrinology 1 (2012): 74–8.\n- Vercellini, P., Vendola, N., Ragni, G., et al. “Abnormal uterine bleeding associated with iron-deficiency anemia. Etiology and role of hysteroscopy.” Journal of Reproductive Medicine 38.7 (1993): 502–4.\n- World Health Organization. WHO recommendations on antenatal care for a positive pregnancy experience. Geneva. WHO (2016).\n- Yan Wang, Lan Huang. “Iron Status in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis.” PLoS One 12.1 (2017): e0169145.\nDownloads\nPublished\nHow to Cite\nIssue\nSection\nLicense\nCopyright (c) 2020 Н. Ю. Педаченко, Т. М. Тутченко, Р. А. Тухтарян\nThis work is licensed under a Creative Commons Attribution 4.0 International License.\nAuthors who publish with this journal agree to the following terms:\n- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.\n- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.","source_license":"CC0","license_restricted":false}